Jay Lalezari, M.D., discusses the BOSS study, the first randomized study to examine the use of a needle-free device for administration of Fuzeon (enfuvirtide, T-20).

Joseph Eron, M.D., discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced patients.

Joseph J. Eron, M.D., reviews highlights of ICAAC, including 48-week data on maraviroc, a head-to-head comparison of darunavir + ritonavir to lopinavir/ritonavir in treatment-naive patients, and the results of a study using interleukin-2 to delay HAART initiation.

Pablo Tebas, M.D., discusses why people who stop taking HIV meds are potentially at a greater risk for cardiovascular disease than if they remain on treatment.

Ben Young, M.D., Ph.D., reviews his presentation, which analyzes the impact of Viread (tenofovir) on the kidney function of people who already have kidney disease.

Trevor Hawkins, M.D., provides an update on his view of the most important studies presented at ICAAC, including data presented on CCR5 inhibitors, and the ARTEMIS trial, in which darunavir (TMC114, Prezista) + ritonavir (RTV, Norvir) compared favorably to lopinavir/ritonavir (LPV/r, Kaletra) in treatment-naive patients.

Michael Silverman, M.D., discusses his poster on the declining prevalence of HIV in pregnant women in Zimbabwe -- a 41% drop that may be due to the country's declining economy.

Tristan Ferry, M.D., discusses his poster on incidence and risk factors for non-AIDS-defining, non-HAART-related severe clinical events.

Matthew Goetz, M.D. discusses his research on the impact of co-receptor tropism on disease progression in treatment-naive patients.

Prakash Sista, Ph.D. discusses how the presence of protease inhibitor mutation I50L is associated with HIV drug resistance to atazanavir (ATV, Reyataz) and increased susceptibility to other protease inhibitors in a variety of protease mutational backgrounds.